🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

7 recruiting trials

for NSCLC Patients With EGFR Activating Mutation

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor NCT07755397Phase 16 sites📍 Surat📍 Bangalore📍 Mumbai Jubilant Therapeutics India Limited · Tests: JBI-778 TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813Phase 21 site📍 Beijing TYK Medicines, Inc · Tests: TY-9591, Osimertinib A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain NCT06741085Phase 28 sites📍 Miami📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: osimertinib, stereotactic radiosurgery (SRS) Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NCT05382728Phase 32 sites📍 Changsha📍 Shanghai TYK Medicines, Inc · Tests: TY-9591, placebo Osimertinib, Osimertinib, placebo TY-9591 EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC NCT07637448Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: EGFR-TKIs Combined with PD-1 Monoclonal Antibody Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial NCT06363734Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Osimertinib plus Dalpiciclib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy